Bial - Portela C S.A.: Parkinson Disease trials

The registry lists 62 Parkinson Disease studies with Bial - Portela C S.A. as lead sponsor. 1 are open to participants now and 28 have results posted.

Phase 1 46Phase 2 5Phase 3 3Phase 4 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world TreatmentRecruitingNCT07145190
• OpiCapone Effect on Motor Fluctuations and pAiNCompletedNCT04986982Phase 4Results posted
• Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of OpicaponeCompletedNCT02305316Phase 1Results posted
• Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersCompletedNCT02305017Phase 1Results posted
• The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02170376Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/BenserazideCompletedNCT02169895Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169479Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/BenserazideCompletedNCT02169466Phase 1Results posted
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/CarbidopaCompletedNCT02169453Phase 1Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedNCT02169440Phase 1Results posted
• An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and MetabolitesCompletedNCT02169427Phase 1Results posted
• Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa PharmacokineticsCompletedNCT02169414Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentCompletedNCT02101190Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young SubjectsCompletedNCT02092168Phase 1Results posted
• Comparative Bioavailability Study of BIA 9-1067 25 mg CapsulesCompletedNCT02071823Phase 1Results posted
• Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067CompletedNCT02071810Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedNCT01568073Phase 3Results posted
• Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedNCT01568047Phase 2Results posted
• A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067CompletedNCT01568034Phase 2Results posted
• Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideCompletedNCT01536366Phase 1Results posted
• Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/BenserazideCompletedNCT01533116Phase 1Results posted
• Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/CarbidopaCompletedNCT01533077Phase 1Results posted
• Effect of Rasagiline on BIA 9-1067 PharmacokineticsCompletedNCT01532141Phase 1Results posted
• Effect of BIA 9-1067 on Rasagiline PharmacokineticsCompletedNCT01532128Phase 1Results posted
• Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedNCT01520987Phase 1Results posted
• A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsCompletedNCT01520727Phase 1Results posted
• Study of BIA 9-1067 to Investigate Its Effect on Levodopa PharmacokineticCompletedNCT01519284Phase 1Results posted
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and MetabolitesCompletedNCT01515891Phase 1Results posted
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.CompletedNCT01227655Phase 3Results posted
• Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE StudyNo longer availableNCT07522606
• REal-life ON PARKinson's - ITaly (REONPARK-IT)Active, not recruitingNCT07403799
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDActive, not recruitingNCT05819359Phase 2
• Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedNCT05220072Phase 1
• eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedNCT04990284Phase 4
• OpicApone Sleep dISorderCompletedNCT04986995Phase 4
• Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedNCT04978597Phase 3
• Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedNCT04265027Phase 1
• Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's DiseaseCompletedNCT03959540
• Relative Bioavailability and Bioequivalence of OpicaponeCompletedNCT03820037Phase 1
• Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedNCT03119194Phase 1
• Effect of Food on OpicaponeCompletedNCT03116308Phase 1
• Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedNCT03116295Phase 1
• Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedNCT03103399Phase 2
• Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgCompletedNCT03097211Phase 1
• Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young SubjectsCompletedNCT03095105Phase 1
• Effect of Food on BIA 6-512 (Trans-resveratrol)CompletedNCT03095092Phase 1
• Effect of BIA 6-512 at Steady-state on the Levodopa PharmacokineticsCompletedNCT03094156Phase 1
• Tolerability and Steady-state Pharmacokinetics of BIA 6-512CompletedNCT03093389Phase 1
• Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa PharmacokineticsCompletedNCT03091868Phase 1
• Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa PharmacokineticsCompletedNCT03091543Phase 1
• Efficacy and Safety of Opicapone in Clinical PracticeCompletedNCT02847442Phase 4
• Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedNCT02834507Phase 2
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazideCompletedNCT02778594Phase 1
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaCompletedNCT02774564Phase 1
• Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202CompletedNCT02772627Phase 1
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesCompletedNCT02772614Phase 1
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)CompletedNCT02763852Phase 1
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)CompletedNCT02763839Phase 1
• Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202CompletedNCT02763800Phase 1
• Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202CompletedNCT02763787Phase 1
• Effect of Opicapone at Steady State on Warfarin PharmacokineticsCompletedNCT02305030Phase 1
• Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenCompletedNCT01532115Phase 1